SNX31 inhibitors refer to a class of chemical compounds designed to target and modulate the activity of the Sorting Nexin 31 (SNX31) protein. SNX31 is a member of the Sorting Nexin (SNX) family, which is primarily involved in regulating intracellular trafficking and endosomal sorting processes within cells. These inhibitors have garnered attention due to their to influence the cellular pathways and functions mediated by SNX31. SNX31, like other SNX proteins, plays a pivotal role in the intricate processes of endocytosis and endosomal sorting. It is known to interact with various endosomal proteins and membrane lipids, contributing to the maintenance of cellular homeostasis and vesicular trafficking.
SNX31 inhibitors are designed to interfere with the normal function of SNX31 by binding to the protein or altering its conformation. By doing so, they can impact the sorting and trafficking of membrane-bound proteins, receptors, and other cellular cargo within endosomes. This can have downstream effects on various cellular processes, including receptor signaling, protein degradation, and recycling. Researchers are particularly interested in understanding the specific mechanisms through which SNX31 inhibitors modulate endosomal sorting and their implications for cell physiology and pathology. As the field of cell biology continues to unravel the intricacies of endosomal trafficking and protein sorting, SNX31 inhibitors may prove to be valuable tools for studying these processes and uncovering novel insights into cellular regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3-kinases, blocking phosphoinositide signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Blocks PI3-kinase activity, disrupting PI3K/Akt signaling. | ||||||
IC-87114 | 371242-69-2 | sc-364509 sc-364509A | 5 mg 50 mg | $140.00 $1060.00 | 1 | |
Selective inhibitor of PI3Kδ, affecting B-cell signaling. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Targets PI3Kδ, primarily in lymphocytes, for cancer therapy. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
Dual PI3K/mTOR inhibitor, impeding PI3K/Akt/mTOR signaling. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
Blocks Akt kinase activity, suppressing downstream pathways. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
Selective PI3K inhibitor disrupting PI3K/Akt/mTOR signaling. | ||||||
GDC-0980 | 1032754-93-0 | sc-364499 sc-364499A | 5 mg 50 mg | $347.00 $1428.00 | ||
Inhibits both PI3K and mTOR, impacting multiple pathways. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Selective PI3Kα inhibitor used for breast cancer | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
Inhibits PI3Kβ, affecting Akt signaling in specific cancers. | ||||||